MCP‐1 promotes T‐lymphocyte differentiation, serves as a chemoattractant and even activates NK cells.40 As lower LASP1 levels lead to a reduced K562 cytokine release and reduced CD107a surface expression on NK cells, lower LASP1 levels in CML patients might contribute to the evasion of CML cells from the immune system, especially since effector NK cells are per se reduced in number and have a limited cytolytic capacity in CML.41 TKI treatment further impairs this cellular immune function.41 This evidence concerns the gene CCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.